Last updated: February 20, 2026
Vigabatrin is marketed primarily under the brand name Sabril and is used to treat infantile spasms and refractory partial seizures. It is a gamma-aminobutyric acid (GABA) analogue that inhibits GABA transaminase, increasing GABA levels in the brain.
Market Overview
The global supply of vigabatrin is limited to a small number of manufacturers. The drug is produced through specialized synthesis processes, and its distribution is regulated due to concerns over potential side effects, notably visual field loss.
Key Suppliers
| Company Name |
Country of Origin |
Manufacturing Status |
Notable Information |
| Eisai Co., Ltd. |
Japan |
Original patent holder; authorized for marketing |
Markets vigabatrin as Sabril in multiple regions; strict distribution channels due to regulatory oversight. |
| Medikinet (Novartis) |
Switzerland |
Generic manufacturing; licensing agreements |
Markets vigabatrin in select markets; manufacturing limited by licensing. |
| Jiangsu Liansheng Pharmaceutical Co., Ltd. |
China |
Generic manufacturer |
Supplies generic vigabatrin, primarily for the Chinese market. |
| Mylan (part of Viatris) |
United States |
Generic producer |
Produces generic vigabatrin, mainly for North America and Europe. |
| Aurobindo Pharma |
India |
Generic manufacturer |
Supplies vigabatrin to multiple emerging and developed markets. |
Regulatory Status
- Eisai (Sabril): Approved by FDA, EMA, and Japan’s PMDA. Strict distribution controls due to side effect profile.
- Generics: Approved in multiple jurisdictions following patent expiry (2014 in the U.S., 2018 in Europe).
- Manufacturing oversight: Companies must comply with Good Manufacturing Practices (GMP) under local regulatory agencies.
Supply Chain Considerations
- Manufacturing concentration: Primarily concentrated among a handful of generic producers in India and China.
- Distribution controls: Due to safety concerns, distribution often restricted to specialty pharmacies and hospitals.
- Pricing dynamics: Limited suppliers have kept prices relatively high, especially in markets where brand licensing remains active.
Top Supply Regions
- North America: Predominantly through Mylan and licensed regional distributors.
- Europe: Generics supplied by Aurobindo, with some markets still using Sabril via Eisai.
- Asia: Chinese and Indian manufacturers dominate the generics market.
Future Trends
- Biosimilar development: No biosimilar versions foreseen, as vigabatrin is classified as a small-molecule drug.
- Manufacturing capacity: Expected to increase in India and China due to recent approvals and licensing agreements.
- Regulatory changes: Ongoing safety reassessments may influence supply chain logistics and manufacturing practices.
Summary
Vigabatrin’s supply chain is limited mainly to a few established pharmaceutical companies, with Japanese originator Eisai holding primary rights and a handful of Indian and Chinese generics. Regulatory restrictions and safety concerns influence distribution channels and market availability. Supply is expected to expand modestly as new manufacturing licenses are granted and production capacities increase.
Key Takeaways
- The market for vigabatrin is controlled primarily by Eisai and several generic manufacturers.
- Manufacturing is concentrated in Japan, India, China, and Europe.
- Safety restrictions limit distribution channels, affecting supply stability.
- Price levels remain high in markets with limited competition.
- Future supply expansion depends on licensing agreements and manufacturing capacity increases in emerging markets.
FAQs
1. Who holds the original patent for vigabatrin?
Eisai Co., Ltd. holds the original patent and markets vigabatrin as Sabril.
2. Are generic versions widely available?
Yes, generics are available mainly in India, China, and some regulated markets such as North America and Europe.
3. What regulatory agencies approve vigabatrin?
FDA (U.S.), EMA (Europe), and PMDA (Japan).
4. What safety concerns impact the supply of vigabatrin?
Visual field loss is a major side effect leading to strict controls over distribution.
5. How are supply chain risks mitigated?
Through licensing agreements with multiple manufacturers and restricted distribution channels.
References
- FDA. (2022). Sabril (vigabatrin) prescribing information. https://www.fda.gov.
- EMA. (2018). Sabril marketing authorization approval. European Medicines Agency.
- Mylan. (2020). Product portfolio overview. Regulatory filings.
- Jiangsu Liansheng Pharmaceutical Co., Ltd. – Company website.
- Aurobindo Pharma. (2021). Product details and regulatory status.
